View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 21, 2020updated 12 Jul 2022 11:57am

Covid-19: First coronavirus vaccine trial submission expected in April

The earliest vaccine for the novel coronavirus in China will be submitted for clinical trials around late April, said China’s Vice Minister of Science and Technology Xu Nanping at a press conference.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Follow the latest updates of the outbreak on our timeline.

The earliest vaccine for the novel coronavirus in China will be submitted for clinical trials around late April, according to China’s vice-minister of science and technology Xu Nanping.

SARS-CoV-2, the new coronavirus that emerged in Wuhan, China in December 2019, has claimed the lives of more than 2,200 people and led to over 76,000 infections across 28 countries.

Companies and researchers worldwide are in a race to develop a vaccine and also effective treatments for the disease caused by SARS-CoV-2, officially named as Covid-19.

While various existing drugs have entered clinical trials, vaccine candidates are still in development or preclinical stages. It is estimated that a coronavirus vaccine will take nearly a year to be market-ready.


See all Coronavirus vaccines and drugs in the pipeline


Initial drug data expected within weeks

In a tweet, the World Health Organization director-general Tedros Adhanom Ghebreyesus said that initial data from the clinical trials of AbbVie’s lopinavir plus ritonavir, and Gilead’s remdisivir is expected to be available in three weeks.

These drugs are prioritised by the WHO R&D Blueprint.

The drugs hold approvals for other indications, allowing them to bypass safety tests in animals. Two accelerated trials are being conducted based on the WHO expert recommendations, reported the Guardian.

A study by the US National Institutes of Health (NIH) demonstrated that Gilead’s antiviral drug, remdesivir, could prevent a type of coronavirus in monkeys.

The drug prevented the Middle East respiratory syndrome coronavirus (MERS-CoV) disease when administered before infection. In infected animals, the drug improved their condition.

In a separate development, China Daily reported that the combination of traditional Chinese medicine with Western drugs has demonstrated effectiveness against the new coronavirus.

State Administration of Traditional Chinese Medicine head was quoted as saying: “A large number of clinical practices have confirmed the effect of the combined treatment of TCM and Western medicine on new coronavirus pneumonia patients.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena